

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Australian Pharmaceutical Industries Limited
ABN 57 000 004 320

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Craig Vincent
Date of last notice	4 February 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	15 October 2021
No. of securities held prior to change	481,833 ordinary shares 416,954 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2018 to 31 August 2021 495,711 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2019 to 31 August 2022 825,400 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2020 to 31 August 2023
Class	Performance rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	160,900 performance rights granted under API's Short Term Incentive Plan (2021)
Number disposed	416,954 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2018 to 31 August 2021
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	No amount is payable by Mr Vincent for the Performance Rights. The Short Term Incentive Plan performance conditions have been met (in part) and these Performance Rights have been granted. After expiry of the deferral period the Performance Rights will vest and Mr Vincent will be entitled to convert each Performance Right into one fully paid API ordinary share, which will be satisfied through on-market purchases.
No. of securities held after change	481,833 ordinary shares 495,711 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2019 to 31 August 2022 825,400 performance rights granted under API's Long Term Incentive Plan with a performance period of 1 September 2020 to 31 August 2023 160,900 performance rights granted under API's Short Term Incentive Plan (2021) (new)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance rights were granted under API's Short Term Incentive Plan (2021) & Performance rights lapsed under API's Long Term Incentive Plan with a performance period of 1 September 2018 to 31 August 2021

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.